X4 Pharmaceuticals, Inc (XFOR) stock
XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.83−0.29 (-9.29%)
Close on Nov 16, 2026Market cap $280.59MP/E –Yield –
X4 Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
X4 Pharmaceuticals's total assets was $231.82M at Sep 30, 2026. For fiscal 2025 it was $290.46M, up 98.3% from the year before. The highest annual figure on record is $290.46M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $290.46M | +98.3% |
| FY2024 | Dec 31, 2024 | $146.45M | -0.6% |
| FY2023 | Dec 31, 2023 | $147.26M | -5.4% |
| FY2022 | Dec 31, 2022 | $155.59M | +32.8% |
| FY2021 | Dec 31, 2021 | $117.18M | -4.6% |
| FY2020 | Dec 31, 2020 | $122.87M | -23.5% |
| FY2019 | Dec 31, 2019 | $160.70M | +1516.0% |
| FY2018 | Dec 31, 2018 | $9.94M | -87.8% |
| FY2017 | Dec 31, 2017 | $81.25M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $231.82M | +41.7% |
| Q2 FY2026 | Jun 30, 2026 | $253.06M | +140.6% |
| Q1 FY2026 | Mar 31, 2026 | $270.28M | +107.9% |
| Q4 FY2025 | Dec 31, 2025 | $290.46M | +98.3% |
| Q3 FY2025 | Sep 30, 2025 | $163.56M | -8.2% |
| Q2 FY2025 | Jun 30, 2025 | $105.17M | -50.1% |
| Q1 FY2025 | Mar 31, 2025 | $130.01M | +15.9% |
| Q4 FY2024 | Dec 31, 2024 | $146.45M | -0.6% |
| Q3 FY2024 | Sep 30, 2024 | $178.17M | +2.7% |
| Q2 FY2024 | Jun 30, 2024 | $210.61M | +69.3% |
| Q1 FY2024 | Mar 31, 2024 | $112.18M | -27.9% |
| Q4 FY2023 | Dec 31, 2023 | $147.26M | +29.9% |
| Q2 FY2023 | Jun 30, 2023 | $173.40M | +114.0% |
| Q1 FY2023 | Mar 31, 2023 | $124.41M | +24.9% |
| Q4 FY2022 | Dec 31, 2022 | $155.59M | +32.8% |
| Q3 FY2022 | Sep 30, 2022 | $113.41M | -5.9% |
| Q2 FY2022 | Jun 30, 2022 | $81.02M | -42.8% |
| Q1 FY2022 | Mar 31, 2022 | $99.63M | -38.1% |
| Q4 FY2021 | Dec 31, 2021 | $117.18M | -4.6% |
| Q3 FY2021 | Sep 30, 2021 | $120.52M | -9.5% |
| Q2 FY2021 | Jun 30, 2021 | $141.66M | -0.6% |
| Q1 FY2021 | Mar 31, 2021 | $161.04M | +4.8% |
| Q4 FY2020 | Dec 31, 2020 | $122.87M | -23.5% |
| Q3 FY2020 | Sep 30, 2020 | $133.13M | +21.5% |
| Q2 FY2020 | Jun 30, 2020 | $142.53M | +6.8% |
| Q1 FY2020 | Mar 31, 2020 | $153.72M | +145.8% |
| Q4 FY2019 | Dec 31, 2019 | $160.70M | +1516.0% |
| Q3 FY2019 | Sep 30, 2019 | $109.54M | +138.6% |
| Q2 FY2019 | Jun 30, 2019 | $133.51M | +133.4% |
| Q1 FY2019 | Mar 31, 2019 | $62.55M | -9.6% |
| Q4 FY2018 | Dec 31, 2018 | $9.94M | -87.8% |
| Q3 FY2018 | Sep 30, 2018 | $45.90M | – |
| Q2 FY2018 | Jun 30, 2018 | $57.21M | – |
| Q1 FY2018 | Mar 31, 2018 | $69.22M | – |
| Q4 FY2017 | Dec 31, 2017 | $81.25M | – |
See a number that looks wrong?